BLOOMFIELD, Conn., July 13, 2023 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its second quarter 2023 financial results on Thursday, August 3, 2023, and will host a conference call the same day.
Second quarter 2023 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows:
Live Call
(888) 566-1889 (Domestic)
(773) 799-3989 (International)
Passcode: 8032023
Replay
(800) 839-1335 (Domestic)
(203) 369-3357 (International)
It is strongly suggested that participants dial in to the conference call by 8:15 a.m. ET on August 3. A replay of the call will be available from 12:30 p.m. ET on August 3 until 11:59 p.m. ET on August 17, 2023. Additionally, the conference call will be available on a live internet webcast at https://investors.thecignagroup.com/events-and-presentations/default.aspx in the Investor Relations section of The Cigna Group's website. Please note that this feature will be in listen-only mode.
A copy of the company's news release and financial supplement will be available on The Cigna Group's website in the Investor Relations section at https://investors.thecignagroup.com/overview/default.aspx, no later than 6:30 a.m. ET on August 3.
About The Cigna Group
The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has more than 165 million customer relationships around the world. Learn more at thecignagroup.com.
Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Justine Sessions
1 (860) 810-6523
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$353.49 |
| Daily Change: | -1.63 -0.46 |
| Daily Volume: | 1,412,524 |
| Market Cap: | US$98.820B |
August 01, 2024 May 23, 2024 March 07, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
